Publicaciones en colaboración con investigadores/as de Instituto Ramón y Cajal de Investigación Sanitaria (22)

2024

  1. Respiratory syncytial virus: A new era

    Revista Espanola de Quimioterapia, Vol. 37, Núm. 2, pp. 134-148

2023

  1. Advantages and disadvantages of maintaining the mandatory use of masks in health centers and nursing homes in Spain. How and when is it justified to maintain it?

    Revista Espanola de Quimioterapia, Vol. 36, Núm. 5, pp. 466-469

  2. Tuberculosis in Spain: An opinion paper

    Revista Espanola de Quimioterapia, Vol. 36, Núm. 6, pp. 562-583

2022

  1. Actions and attitudes on the immunized patients against SARS-CoV-2

    Revista Espanola de Quimioterapia, Vol. 35, Núm. 1, pp. 7-15

  2. COVID in Pediatric Age: an opinion paper

    Revista Espanola de Quimioterapia, Vol. 35, Núm. 4, pp. 333-343

  3. COVID-19: Some unresolved issues

    Revista Espanola de Quimioterapia, Vol. 35, Núm. 5, pp. 421-434

  4. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

  5. Lessons from COVID-19 for future disasters: an opinion paper

    Revista Espanola de Quimioterapia, Vol. 35, Núm. 5, pp. 444-454

  6. Monkeypox in humans: a new outbreak

    Revista Espanola de Quimioterapia, Vol. 35, Núm. 6, pp. 509-518

  7. Persistence and viability of SARS-CoV-2 in primary infection and reinfections

    Revista Espanola de Quimioterapia, Vol. 35, Núm. 1, pp. 1-6

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

  2. New variants of SARS-CoV-2

    Revista Espanola de Quimioterapia, Vol. 34, Núm. 5, pp. 419-428

  3. Post-covid syndrome: A reflection and opinion paper

    Revista Espanola de Quimioterapia, Vol. 34, Núm. 4, pp. 269-279

2020

  1. Frailty, markers of immune activation and oxidative stress in HIV infected elderly

    PLoS ONE, Vol. 15, Núm. 3

  2. Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 195-202

2018

  1. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

    American Journal of Transplantation, Vol. 18, Núm. 10, pp. 2513-2522

2016

  1. HIV infection results in metabolic alterations in the gut microbiota different from those induced by other diseases

    Scientific Reports, Vol. 6

  2. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

2014

  1. Different trends of transmitted HIV-1 drug resistance in Madrid, Spain, among risk groups in the last decade

    Archives of Virology, Vol. 159, Núm. 5, pp. 1079-1087